"The Evaluation of Stimulant Withdrawal" (MARC)
This study is currently recruiting participants.
Verified by National Institute on Drug Abuse (NIDA) March 2007
Purpose
The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence (1) improves their ability to stay in treatment longer, (2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the time they remain abstinent from methamphetamine.
Condition |
Intervention |
Phase |
Anxiety
Relapse
Substance Addiction |
Drug: Coreg |
Phase II |
MedlinePlus related topics: Drug Abuse
Study Type: Interventional
Study Design: Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Scientific Component IV: Pharmacotherapy to Prevent Methamphetamine Relapse